milliporesigma videos

41. The Blazar® Platform In A Minute 3/12/2021

    The Blazar® Rodent Panel from the BioReliance® portfolio can speed cell line characterization and bulk harvest lot release testing. This degenerate PCR-based method accelerates characterization by reducing timelines by up to 80% and replaces the use of animals.

42. Level Up With Product Characterization 3/12/2021

    In the race to bring a new biotherapeutic to market, unexpected obstacles can slow you down or even knock you back a few steps. But with the right information at the right time, and an experienced partner to provide scientific, regulatory, and bioprocessing guidance and support, you can find a smoother, faster path to the finish line.

43. CHO Fed-batch Portfolio: Cellvento® And EX-CELL® Advanced Media And Feeds 3/11/2021

    Cellvento® and EX-CELL® Advanced cell culture media supports consistent growth and performance from development to production. Get the enhanced performance, assured regulatory compliance and the security of supply necessary in today’s biopharmaceutical environment.

44. Bio4C ProcessPad™ Product Overview 5/19/2020

    Introducing Bio4C ProcessPad™ Software, part of the BioContinuum™ Platform.

45. Reduce The Level Of Host Cell Protein In The Bioreactor Harvest 12/11/2019

    Host cell proteins (HCPs) are an inevitable byproduct of biologics manufacturing and can have an impact on product quality and efficacy as well as patient safety. Processes designed to remove HCPs from the bioreactor harvest must not only be successful in achieving acceptable limits, but also be scalable. Learn how we helped our client reduce the level of HCPs in the bioreactor harvest prior to a production run to supply drug substance for a scheduled Phase 1 clinical trial in a very tight timeline.

46. Optimize The Formulation Of A Monoclonal Antibody 12/11/2019

    You have a molecule of interest and need an effective formulation to maximize stability and minimize aggregation. As with all formulations, it is essential that the buffers and excipients ensure stability of the drug substance, be compatible with each other and meet regulatory requirements. An emerging biotech company sought our help in developing a formulation for a monoclonal antibody. Learn how we have delivered an optimized formulation for this customer in three months.

47. Increase The Titer Of A Difficult To Express Molecule 12/11/2019

    What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development?  A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment. Learn how our client achieved a nearly 4-fold titer increase.

48. How To Generate A High-Producing Cell Line In Fast-Track Mode 12/11/2019

    Cell line development processes can be quite time consuming and labor intensive. When our clients have a very challenging timeline, we can begin process development in parallel with cell line development, further accelerating timelines. What are the risks and how do you minimize risk?

49. Accelerate Identification Of High-Producing Cell Lines 12/11/2019

    When companies are putting in place an upstream process, a critical step is generation of a cell line expressing the protein of interest. Unfortunately, the search for the best-producing clone is often compared with looking for a needle in a haystack. Watch our video to learn about our mini-pool approach and the value of automated systems to efficiently create, screen and isolate high producing clones with reduced costs.

50. Biotherapy Characterization: Cell-Based Assays 7/17/2019

    MilliporeSigma Senior Scientist Agata Burzawa, MSc, explains how we can provide you with rich data sets to help you understand your complex biotherapy faster. Using limited volumes of samples for testing, our scientists employ leading technologies that integrate cytokine release monitoring with immunophenotyping of cells within the same sample.